相关实验视频

Updated: Jul 11, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

在骨髓纤维化临床试验中确定疾病修饰潜力

David M Ross¹, Steven W Lane², Claire N Harrison³

¹Department of Haematology, Royal Adelaide Hospital, Adelaide, Australia.

|August 22, 2024

概括

针对骨髓纤维化 (MF) 的新药应该使用分子终点,而不是JAK抑制剂效应,以更好地评估疾病修饰和加速临床试验,以改善患者的治疗结果.

科学领域:

血液恶性瘤研究研究
临床试验设计和终点

背景情况:

总体存活率是新的血液性恶性瘤药物的主要目标.
替代终点可以加快结果评估,但必须准确地反映疾病的变化.
目前用于骨髓纤维化 (MF) 的Janus激酶 (JAK) 抑制剂可以改善症状,但不能改善疾病的自然史.

研究的目的:

评估当前临床试验终点对髓纤维化 (MF) 的适用性.
提出替代的分子终点来评估MF药物开发中的疾病修饰.
加快针对多发性肺炎的新药的临床开发.

主要方法:

在血液恶性瘤中审查已确立的代用终点.
分析JAK抑制剂对MF自然史的影响.
建议利用分子终点,例如减轻突变负担.

主要成果:

已确立的MF试验终点主要衡量症状负担和腹壮大,而不是疾病改变.
尽管症状有所改善,但JAK抑制剂对MF自然史的影响有限.
目前的试验终点可能会阻碍开发真正改变MF疾病的疗法.

结论:

重新考虑临床试验终点对于推进MF治疗至关重要.
分子终点,比如减少突变负担,提供了更准确的疾病修饰测量.
采用新的终点将加速开发有效的骨髓纤维化治疗方法.

更多相关视频

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...